affiniatx.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $179.09MM
Affinia Therapeutics’ purpose is to develop gene therapies that can have a transformative impact on people affected by devastating rare and non-rare diseases and methodically engineers novel AAV vectors and regulatory elements to make gene therapies with potentially improved tissue tropism, cell specificity, safety, and yields.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
05/03/2021 | Series B | $110MM | $xx.xx | $365.7MM | EcoR1 Capital, Farallon Capital Management, Avidity Partners, Casdin Capital, GV, Octagon Capital, Perceptive Advisors, RA Capital Management, TCG Crossover, Woodline Partners LP, Atlas Venture, F-Prime Capital, Lonza, Mass General Brigham Ventures, New Enterprise Associates | |
Price per Share
$xx.xx
Shares Outstanding
20,813,930
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
EcoR1 Capital, Farallon Capital Management, Avidity Partners, Casdin Capital, GV, Octagon Capital, Perceptive Advisors, RA Capital Management, TCG Crossover, Woodline Partners LP, Atlas Venture, F-Prime Capital, Lonza, Mass General Brigham Ventures, New Enterprise Associates
|
||||||
03/31/2020 | Series A | $60.57MM | $xx.xx | $116.71MM | F-Prime Capital, New Enterprise Associates, Atlas Venture, Alexandria Venture Investments, Lonza, Partners Innovation Fund | |
Price per Share
$xx.xx
Shares Outstanding
23,736,223
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
F-Prime Capital, New Enterprise Associates, Atlas Venture, Alexandria Venture Investments, Lonza, Partners Innovation Fund
|
||||||
11/05/2019 | Series A-1 | $8.52MM | $xx.xx | $42.61MM | F-Prime Capital, New Enterprise Associates, Alexandria Venture Investments, Lonza, Partners Innovation Fund | |
Price per Share
$xx.xx
Shares Outstanding
3,706,187
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
F-Prime Capital, New Enterprise Associates, Alexandria Venture Investments, Lonza, Partners Innovation Fund
|